BRPI0818928A2 - moléculas de ligação nogo-a aperfeiçoadas e uso farmacêutico destas - Google Patents

moléculas de ligação nogo-a aperfeiçoadas e uso farmacêutico destas

Info

Publication number
BRPI0818928A2
BRPI0818928A2 BRPI0818928A BRPI0818928A BRPI0818928A2 BR PI0818928 A2 BRPI0818928 A2 BR PI0818928A2 BR PI0818928 A BRPI0818928 A BR PI0818928A BR PI0818928 A BRPI0818928 A BR PI0818928A BR PI0818928 A2 BRPI0818928 A2 BR PI0818928A2
Authority
BR
Brazil
Prior art keywords
nogo
improved
binding molecules
pharmaceutical use
pharmaceutical
Prior art date
Application number
BRPI0818928A
Other languages
English (en)
Inventor
Vitaliti Alessandra
Khusro Mir Anis
Barske Carmen
E Schwab Martin
Frentzel Stefan
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818928(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of BRPI0818928A2 publication Critical patent/BRPI0818928A2/pt
Publication of BRPI0818928B1 publication Critical patent/BRPI0818928B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0818928-5A 2007-11-02 2008-10-27 Moléculas de ligação a nogo-a isoladas, seu método de produção e seu uso, polinucleotídeo isolado, vetor e sistema de expressão, célula hospedeira isolada, e composição farmacêutica BRPI0818928B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US174107P 2007-11-02 2007-11-02
US61/001,741 2007-11-02
EP07119847.7 2007-11-02
EP07119847 2007-11-02
PCT/EP2008/064501 WO2009056509A1 (en) 2007-11-02 2008-10-27 Improved nogo-a binding molecules and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
BRPI0818928A2 true BRPI0818928A2 (pt) 2017-05-16
BRPI0818928B1 BRPI0818928B1 (pt) 2021-12-07

Family

ID=39156235

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818928-5A BRPI0818928B1 (pt) 2007-11-02 2008-10-27 Moléculas de ligação a nogo-a isoladas, seu método de produção e seu uso, polinucleotídeo isolado, vetor e sistema de expressão, célula hospedeira isolada, e composição farmacêutica

Country Status (30)

Country Link
US (2) US8163285B2 (pt)
EP (1) EP2207808B1 (pt)
JP (1) JP5698534B2 (pt)
KR (1) KR101574814B1 (pt)
CN (1) CN101910200B (pt)
AR (1) AR072934A1 (pt)
AU (1) AU2008317724B2 (pt)
BR (1) BRPI0818928B1 (pt)
CA (1) CA2704357C (pt)
CL (1) CL2008003240A1 (pt)
CO (1) CO6270357A2 (pt)
CY (1) CY1114345T1 (pt)
DK (1) DK2207808T3 (pt)
ES (1) ES2425768T3 (pt)
HR (1) HRP20130699T1 (pt)
IL (2) IL205357A (pt)
JO (1) JO2876B1 (pt)
MA (1) MA31805B1 (pt)
MX (1) MX2010004831A (pt)
MY (1) MY149546A (pt)
NZ (1) NZ584911A (pt)
PE (1) PE20090981A1 (pt)
PL (1) PL2207808T3 (pt)
PT (1) PT2207808E (pt)
RU (1) RU2513697C2 (pt)
SI (1) SI2207808T1 (pt)
TN (1) TN2010000199A1 (pt)
TW (1) TWI429656B (pt)
WO (1) WO2009056509A1 (pt)
ZA (1) ZA201002799B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
AU2013285493A1 (en) 2012-07-05 2015-01-22 Glaxo Group Limited Optimum dose regime of an anti-Nogo-A antibody in the treatment of amyotrophic lateral sclerosis
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
US20230399390A1 (en) 2019-10-24 2023-12-14 Novago Therapeutics Ag Novel anti-nogo-a antibodies
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2085326T3 (es) 1989-02-13 1996-06-01 Schering Ag Activador de plasminogeno salivar del murcielago vampiro vpa-alfa1.
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
CN101684155A (zh) * 1998-11-06 2010-03-31 苏黎世大学 Nogo基因的核苷酸序列和蛋白序列以及基于其的方法
CN1234730C (zh) * 2001-12-30 2006-01-04 上海中科伍佰豪生物工程有限公司 鼠抗氯霉素单克隆抗体及其用途
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
GB0329684D0 (en) * 2003-12-22 2004-01-28 Glaxo Group Ltd Method
EP2213684A3 (en) 2003-12-22 2011-05-18 Glaxo Group Limited Nogo-a antibodies for the treatment of Alzheimer disease
WO2006028197A1 (ja) 2004-09-06 2006-03-16 Kirin Beer Kabushiki Kaisha 抗a33抗体
HRP20120851T1 (hr) * 2005-07-05 2012-11-30 Glaxo Group Limited Humanizirana protutijela specifiäśna za nogo-a i njihova farmaceutska upotreba
GB0525662D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
WO2008011446A2 (en) 2006-07-18 2008-01-24 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
CL2008003241A1 (es) 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR101039751B1 (ko) 2008-10-16 2011-06-09 한국생명공학연구원 Ｔｍｐｒｓｓ４―특이적인 인간항체

Also Published As

Publication number Publication date
US8163285B2 (en) 2012-04-24
EP2207808B1 (en) 2013-05-08
CN101910200A (zh) 2010-12-08
JO2876B1 (en) 2015-03-15
MA31805B1 (fr) 2010-10-01
AR072934A1 (es) 2010-09-29
IL221723A0 (en) 2012-10-31
CL2008003240A1 (es) 2009-06-05
JP2011502476A (ja) 2011-01-27
AU2008317724B2 (en) 2011-06-02
TWI429656B (zh) 2014-03-11
IL221723A (en) 2014-08-31
RU2010122044A (ru) 2011-12-10
ZA201002799B (en) 2011-01-26
IL205357A (en) 2014-08-31
CN101910200B (zh) 2013-12-18
CY1114345T1 (el) 2016-08-31
ES2425768T3 (es) 2013-10-17
TN2010000199A1 (en) 2011-11-11
KR101574814B1 (ko) 2015-12-04
US20110027284A1 (en) 2011-02-03
PL2207808T3 (pl) 2013-11-29
MX2010004831A (es) 2010-05-21
EP2207808A1 (en) 2010-07-21
NZ584911A (en) 2011-08-26
US20120171215A1 (en) 2012-07-05
MY149546A (en) 2013-09-13
CO6270357A2 (es) 2011-04-20
JP5698534B2 (ja) 2015-04-08
SI2207808T1 (sl) 2013-09-30
HK1143597A1 (en) 2011-01-07
CA2704357A1 (en) 2009-05-07
IL205357A0 (en) 2010-12-30
BRPI0818928B1 (pt) 2021-12-07
TW200934791A (en) 2009-08-16
KR20100100848A (ko) 2010-09-15
DK2207808T3 (da) 2013-08-05
WO2009056509A1 (en) 2009-05-07
HRP20130699T1 (hr) 2013-11-22
PT2207808E (pt) 2013-08-26
PE20090981A1 (es) 2009-08-13
CA2704357C (en) 2016-06-21
RU2513697C2 (ru) 2014-04-20
US8758754B2 (en) 2014-06-24
AU2008317724A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
ATE502960T1 (de) Lingo bindende moleküle und pharmazeutische verwendung davon
LTPA2018005I1 (lt) Farmacinė kompozicija
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI0821110A2 (pt) Anticorpo anti nr-10 e uso do mesmo
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
BRPI0820457A2 (pt) Fluidos de ruptura e métodos de uso dos mesmos
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI0821924A2 (pt) Moléculas de ligação baseadas em fibronectina melhoradas e seu uso
DE602007010795D1 (de) Blattsauger und -häcksler
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
DE112008002470A5 (de) Filterelement und Filtersystem
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
HUE037061T2 (hu) Specifikusan kötõdõ fehérjék és alkalmazásuk
BRPI0821668A2 (pt) Uso
HRP20160859T1 (hr) Modificirani proteini rsv f i postupci njihove upotrebe
BRPI0919438A2 (pt) mistura de poliésteres, e, uso das misturas de poliésteres
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
LTC2502996I2 (lt) Anti-FGF23 antikūnas ir jį apimanti farmacinė kompozicija
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI NO 2635 DE 06/07/2021.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2694 DE 23-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.